Mihai Ioan Truica

Featured in: Favicon

Articles

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC - Nature Communications

Jan 7, 2024 | nature.com | Christina Yu |James Parrott |Edward Schaeffer |Vishal Kothari |Sarki A. Abdulkadir |Mihai Ioan Truica | +3 more

AbstractHeterogeneous response to Enzalutamide, a second-generation androgen receptor signaling inhibitor, is a central problem in castration-resistant prostate cancer (CRPC) management. Genome-wide systems investigation of mechanisms that govern Enzalutamide resistance promise to elucidate markers of heterogeneous treatment response and salvage therapies for CRPC patients.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.